Assess somatic small-variant oncogenicity
Which methods help classify somatic SNVs and small indels while preserving uncertainty and the relevant gene mechanism?
Evidence collection plan
Collection plannedEvidence collection is planned for this question. The plan defines a comparison to investigate; it does not establish model performance or suitability.
Comparison question
Does a proposed method improve independent oncogenicity classification or review efficiency over explicit conventional criteria while retaining calibrated unresolved results?
Baselines to include
- ClinGen/CGC/VICC criteria-based review under a pinned specification
- A relevant specialised predictor assessed only within its actual output scope
Outcomes to measure
- Category precision/recall and criteria fidelity
- Calibration, abstention and unresolved-case coverage
- Expert review effort, measured separately from treatment outcomes
Validation requirements
- Use oncogenicity-specific labels with evidence, review status and dates.
- Hold out allelic series, residues, studies and genes where unseen-gene transfer is intended.
- Audit training and assertion overlap, including predictor contributions to labels.
- Preserve tumour, assay and gene-mechanism context.
- Use independent qualified somatic-variant adjudication and justified negative or uncertain examples.
Next collection task
Assemble a provenance table of oncogenicity assertions and orthogonal functional studies, including label-leakage exclusions and independently reviewable uncertain examples.
Your decision and inputs
Choose methods that support evidence-based oncogenicity review of somatic small variants and identify when the available evidence remains insufficient.
- Who this is for
- Somatic variant curators; Molecular pathologists evaluating interpretation methods
- Context
- Clinical research
- Inputs
- Variant, genome build, transcript, allele fraction, quality and confidence in somatic origin
- Tumour context, gene mechanism and dated oncogenicity-specific assertions
- Functional studies and the applicable criteria specification
- Expected output
- An oncogenicity classification or unresolved assessment with constituent criteria, conflicting findings and evidence needs.
- Biological setting
- SNVs and small indels, with separate protocols for oncogene missense and tumour-suppressor loss-of-function mechanisms.
Outside this use case
- Inherited predisposition, fusions, rearrangements and copy-number variants require separate interpretation protocols.
- Oncogenicity and molecular activity do not establish drug response or clinical actionability.
- Germline-benign labels are not automatically valid somatic negative controls.
What this establishes for clinical research
Clinical research on somatic interpretation support. Tumour-only sequencing does not establish somatic origin, and therapeutic relevance needs a separate context-specific review.
Which evaluations inform this question?
No model comparison has been collected for this question yet.
Relevant methods and studies may exist outside this collection.
What evidence is still missing?
- Independent oncogenicity assertions and orthogonal functional evidence remain to be assembled with uncertain and negative examples.
- Qualified somatic reviewers are needed to adjudicate criteria and evidence separately from the method being tested.
- Older functional datasets and curated assertions may overlap model training or include predictor-derived evidence.
Sources and review
Automated source review · 2026-09-28 · Codex
Automated review of Rewire's workflow definition and sourced research brief against the agreed exploration and backlog. No human expert approval, model-applicability assessment or clinical validation is claimed.
- Rewire clinical use-case priorities: workflow definitions and evidence plans · Original source ↗
C4 — Somatic small-variant oncogenicity
Release provenance and downloads
Release 2026-09-28-c7b5ac6d34f2
Use-case input digest a0dd27a5f430ec387d309fd6e8615083250873ce4cff5e882c6fb8458ef80e95
Download questions, collection plans and review metadata (JSON) · Verify release checksums
Question use-case-somatic-small-variant-oncogenicity. Any numerical results on this page come from this release's existing evaluation records.